Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trajan Group Holdings Ltd ( (AU:TRJ) ) just unveiled an update.
Trajan Group Holdings Limited, a global analytical science and device company specialising in life science tools for biological, food and environmental analysis, operates more than seven manufacturing sites across the U.S., Australia, Europe and Malaysia and is focused on decentralised, personalised healthcare technologies. The company has appointed long-serving finance executive Simon Billingham as Interim Chief Financial Officer and Interim Joint Company Secretary, replacing outgoing CFO Alister Hodges from 1 May 2026, in a move the CEO says will ensure continuity as Trajan searches for a permanent finance chief later in the year.
Billingham, who joined Trajan in 2011 after beginning his career at Deloitte UK, has held roles including European Financial Controller and General Manager of Finance, giving him enterprise-wide financial oversight and close involvement in the company’s IPO and acquisition program. His elevation to interim CFO signals a preference for internal succession, likely supporting operational stability and reassuring investors and other stakeholders during the leadership transition in the finance function.
The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.
More about Trajan Group Holdings Ltd
Trajan Group Holdings Limited is a global developer and manufacturer of analytical and life sciences products and devices, focused on enabling science that benefits personal health through advanced tools and solutions. Its products are used to analyse biological, food and environmental samples, and the company is building technologies that support decentralised, personalised, data-based healthcare, operating with more than 600 staff across manufacturing sites in the U.S., Australia, Europe and Malaysia.
Average Trading Volume: 39,905
Technical Sentiment Signal: Sell
Current Market Cap: A$60.27M
For a thorough assessment of TRJ stock, go to TipRanks’ Stock Analysis page.